First Berlin reiterates Buy on Cantourage, keeps price target at EUR 11

• First Berlin Equity Research reiterated a Buy rating on Cantourage, keeping its EUR 11 price target on July 16, 2026.
• Report flagged the launch of proprietary medical-cannabis brand gramz. as a strategic shift toward outright raw-material purchases to lift margins.
• Early sell-through was described as encouraging, with added control over product selection, pricing, positioning.
• Germany’s revised reimbursement rules were seen as limited risk, affecting reimbursed flower products that represent under 10% of the market.
• First Berlin maintained 2026 expectations for an 11.5% EBITDA margin, citing gramz. as supportive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cantourage Group SE published the original content used to generate this news brief via EQS News (Ref. ID: rc_26196) on July 16, 2026, and is solely responsible for the information contained therein.